Pulmonx Co. (NASDAQ:LUNG) Stake Trimmed by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC cut its position in shares of Pulmonx Co. (NASDAQ:LUNG) by 29.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 135,500 shares of the company’s stock after selling 55,300 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in Pulmonx were worth $920,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Barclays PLC boosted its stake in Pulmonx by 1.8% in the 3rd quarter. Barclays PLC now owns 94,109 shares of the company’s stock worth $780,000 after purchasing an additional 1,679 shares during the period. Charles Schwab Investment Management Inc. raised its position in Pulmonx by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock valued at $2,142,000 after buying an additional 2,363 shares during the period. Rhumbline Advisers boosted its position in Pulmonx by 4.9% during the 4th quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock worth $363,000 after acquiring an additional 2,488 shares during the period. American Century Companies Inc. grew its stake in Pulmonx by 8.8% during the 4th quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock valued at $236,000 after acquiring an additional 2,810 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Pulmonx by 27.0% in the 4th quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock valued at $106,000 after purchasing an additional 3,310 shares during the period. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Pulmonx Trading Down 1.2 %

Pulmonx stock opened at $3.64 on Friday. Pulmonx Co. has a one year low of $3.37 and a one year high of $9.41. The company’s fifty day moving average price is $6.02 and its two-hundred day moving average price is $6.45. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The company has a market capitalization of $146.30 million, a price-to-earnings ratio of -2.52 and a beta of 0.65.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The business had revenue of $22.54 million for the quarter, compared to analyst estimates of $22.03 million. On average, analysts forecast that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on LUNG shares. Piper Sandler reaffirmed an “overweight” rating and set a $9.00 price objective (down from $10.00) on shares of Pulmonx in a research report on Thursday, May 1st. Citigroup assumed coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating on the stock. Morgan Stanley began coverage on Pulmonx in a research report on Monday, March 10th. They set an “equal weight” rating for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Pulmonx in a research report on Thursday, May 1st. Finally, Jefferies Financial Group assumed coverage on Pulmonx in a research note on Monday, March 10th. They set a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Pulmonx currently has an average rating of “Moderate Buy” and an average price target of $12.07.

Insider Transactions at Pulmonx

In related news, insider Geoffrey Beran Rose sold 5,779 shares of Pulmonx stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.13, for a total value of $41,204.27. Following the transaction, the insider now owns 285,278 shares in the company, valued at $2,034,032.14. This trade represents a 1.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Glendon E. French III sold 55,453 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $8.28, for a total transaction of $459,150.84. Following the sale, the director now owns 1,011,974 shares of the company’s stock, valued at $8,379,144.72. This trade represents a 5.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 145,660 shares of company stock worth $1,128,484. 6.80% of the stock is owned by insiders.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.